CeGaT

With the new certification in hand, the company plans to expand its business in the US through its Pennsylvania-based subsidiary, B. Braun CeGaT.

The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.

Revisions to the reimbursement catalog went into effect July 1, but stakeholders are quarreling about a pre-authorization requirement in court.

Over the last half year, CeGaT lowered turnaround times and prices for its assays, and its lab recently passed CAP inspection.

A medical genetics practice's lawsuit against a government insurance administrator points to continued uncertainty about reimbursement for NGS testing in Germany.

Cenata, based in Tübingen, has run more than 1,000 samples since it started offering the Harmony test in May.

NEW YORK (GenomeWeb) – N-of-One said this week that it has been selected by CeGaT to provide interpret data from its next-generation sequencing-based oncology tests.

NEW YORK (GenomeWeb) – B. Braun CeGaT, the recently-founded US subsidiary of German genetic diagnostics firm CeGaT and its minority stakeholder B. Braun, will initially offer molecular diagnostic testing services through CeGaT's German laboratory but plans to establish a US lab in the long run.

NEW YORK (GenomeWeb) – B Braun Medical US and Tuebingen, Germany-based CeGaT today announced the launch of a US company offering next-generation sequencing-based diagnostics.

Pages

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.